Date: 2014-11-24
Type of information: Collaboration agreement
Compound: allogeneic Chimeric Antigen Receptor T-cells (CAR-T)
Company: Janssen Biotech, a J&J company (USA - NJ) Transposagen Biopharmaceuticals (USA - KY)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration licensing
Action mechanism: cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy.
Disease: undisclosed cancers
Details: * On November 24, 2014, Transposagen Biopharmaceuticals, a private biotechnology company, announced they have entered into a research collaboration and worldwide license agreement with Janssen Biotech, to develop allogeneic Chimeric Antigen Receptor T-cells (CAR-T). Transposagen will be using its proprietary genome editing technologies, including the piggyBac™ Footprint-Free™ Gene Editing System, to create the allogeneic CAR-T therapies. Under the agreement, Janssen has exclusive rights to any allogeneic CAR-T therapy that is jointly developed by Transposagen and Janssen. In addition, Janssen has received a non-exclusive research license to utilize Transposagen’s proprietary gene editing technologies for gene and cell therapy solutions for treating diseases with significant unmet medical need. Transposagen will retain the rights to develop autologous CAR-T therapies and CAR-T therapies using Natural Killer (NK) cells or NK-like cells. Transposagen will enter into a 3-year research collaboration with Janssen whereby both companies will work together on preclinical research. Janssen will be responsible for manufacturing and commercialization of allogeneic CAR-T therapies.
Financial terms: Janssen will pay Transposagen up to $292 million per CAR-T therapeutic, which includes an up-front fee and potential development, regulatory, and commercial milestone payments. Transposagen will also receive tiered royalties on net sales of any allogeneic CAR-T products that are commercialized by Janssen.
Latest news:
